BPC-157: reconstitution and dose ranges
> Updated:
Human schedule
In described protocols BPC-157 is given by subcutaneous (SubQ) injection from a solution reconstituted with bacteriostatic water. The figures below are a generalized reference drawn from research literature and clinic protocols, not a prescription.
This is a concise reference to regimens described for adults; it is not an individual prescription.
A search for BPC-157 dosing usually means one practical question: how many doses to split the daily amount into. The table below answers exactly that, not why the peptide is used in research to begin with.
| Period / condition | Dose | Escalation |
|---|---|---|
| Start | 250 mcg once daily, subcutaneous | Starting dose |
| Extended regimen | 500 mcg/day (125–250 mcg AM + PM) | Increase if needed |
| Upper bound (4–6 week cycle) | up to 800 mcg/day | Maximum in this schedule |
Practical dosage and effect notes
Controlled human dosing studies for BPC-157 are essentially absent: most dose-response data come from animal work, and the regimens on this page are drawn from research protocols and reconstitution practice, not from phase I–III clinical trials.
The split-dose logic (125–250 mcg AM and PM instead of 500 mcg in one shot) rests on pharmacological caution, not a measured human half-life: a short peptide in aqueous solution is unstable at room temperature, so smaller, more frequent doses reduce both concentration variability and how much of the reconstituted solution degrades between injections. The 800 mcg/day upper bound in this schedule is a reference point drawn from described protocols, not a proven effectiveness threshold.
This is background for planning a research protocol, not a medical recommendation and not instructions for self-administration.
This reference is research-use material. The information is not medical advice and is not intended for diagnosis, treatment or prevention of disease.